Take Control of your Clostridium difficile Research
ATCC® has taken the guesswork out of choosing control strains for Clostridium difficile research by creating a uniquely-designed panel of clinical isolates, including:
- Representatives of each known toxinotype
The ATCC Clostridium difficile Panel (ATCC® MP-4) is comprised of 8 clinical isolates representing each one of the known C. difficile toxinotypes including types 0, IIIb, IIIc, (tcdA-, tcdB-), V, VIII, XII, and XXII.
- Improved characterization profiles
Each strain in the ATCC® MP-4 Panel is tested for toxinotype, the presence or absence of binary toxin, Enzyme Immuno Assay (EIA) results, and ribotype. A complete listing of all Clostridium difficile strains tested by ATCC is also available.
- Strains indicated in major outbreaks
Significant strains incorporated into the ATCC Clostridium difficile Panel (ATCC® MP-4) include an epidemic strain implicated in numerous outbreaks across North America ( ATCC® BAA-1870) and a toxinotype V strain ( ATCC® BAA-1875) strongly associated with food-producing-animal infections in Europe and the United States.
ATCC also offers Custom DNA Extraction for each microbial strain included in the panel, as well as normal human foreskin fibroblasts that can be used in Clostridium difficile cytotoxicity neutralization assays, including:
- ATCC® CRL-2429 (CCD-1112Sk)
- ATCC® CRL-2522 (BJ)
- ATCC® SCRC-1041 (HFF-1)
- ATCC® PCS-201-010 (Primary neonatal foreskin fibroblasts)
ATCC has been the globally trusted resource for biological materials and reference reagents for over 85 years. ATCC cultures provide consistency in research applications, ensuring reproducible and reliable data.
Tags: Clostridium difficile, Toxins, Clostridium
Date Published: July 27, 2012
Source article link: ATCC » company contact details
New Primer Pairs for LDTs for P. jirovecii, Group C and G Strep
FDA Clearance for ARIES C. difficile Assay Detecting both Toxin A and B
FDA Clearance for Solana® C. difficile Molecular Assay
Mobidiag, Molecular In Vitro Solutions for Syndromic Diagnostics
Baker Ruskinn Launches New Anaerobic and Microaerophilic Workstations